U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H26ClN7O2S
Molecular Weight 488.006
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DASATINIB ANHYDROUS

SMILES

CC1=NC(NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)=CC(=N1)N4CCN(CCO)CC4

InChI

InChIKey=ZBNZXTGUTAYRHI-UHFFFAOYSA-N
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

HIDE SMILES / InChI
Molecular Formula C22H26ClN7O2S
Molecular Weight 488.006
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:26:50 UTC 2023
Edited
by admin
on Fri Dec 15 16:26:50 UTC 2023
Record UNII
X78UG0A0RN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DASATINIB ANHYDROUS
Common Name English
BMS-354825
Code English
5-THIAZOLECARBOXAMIDE, N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)-2-METHYL-4-PYRIMIDINYL)AMINO)-
Systematic Name English
dasatinib [INN]
Common Name English
Dasatinib [WHO-DD]
Common Name English
DASATINIB [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C155700
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
NDF-RT N0000175605
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
WHO-ATC L01XE06
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
NDF-RT N0000175076
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
Code System Code Type Description
RXCUI
1546019
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY RxNorm
NDF-RT
N0000182141
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
MERCK INDEX
m4101
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C74556
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID4040979
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
EVMPD
SUB23322
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
CHEBI
49375
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
PUBCHEM
3062316
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
INN
8712
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
DRUG BANK
DB01254
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
CAS
302962-49-8
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
DAILYMED
X78UG0A0RN
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
FDA UNII
X78UG0A0RN
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
SMS_ID
100000088015
Created by admin on Fri Dec 15 16:26:51 UTC 2023 , Edited by admin on Fri Dec 15 16:26:51 UTC 2023
PRIMARY
Related Record Type Details
EPHRIN TYPE-A RECEPTOR 2
TARGET -> INHIBITOR
IC50
Structure of DASATINIB (S)-PROPYLENE GLYCOLATE
SOLVATE->ANHYDROUS
Structure of DASATINIB ANHYDROUS
EXCRETED UNCHANGED
URINE
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
TARGET -> INHIBITOR
IC50
Structure of DASATINIB
SOLVATE->ANHYDROUS
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA
TARGET -> INHIBITOR
IC50
BCR-ABL KINASE T315I MUTANT (IMATINIB RESISTANT)
RESISTANT TARGET->INHIBITOR
Structure of DASATINIB ANHYDROUS
EXCRETED UNCHANGED
FECAL
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
with no concentration dependence over the range of 100–500 ng/mL
BINDING
Structure of DASATINIB PROPYLENE GLYCOLATE
SOLVATE->ANHYDROUS
Structure of Dasatinib Laurylsulfate
SALT/SOLVATE -> PARENT
TYROSINE-PROTEIN KINASE LCK
TARGET -> INHIBITOR
IC50
MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT
TARGET -> INHIBITOR
IC50
TYROSINE-PROTEIN KINASE YES
TARGET -> INHIBITOR
IC50
Structure of DASATINIB
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BCR-ABL KINASE
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
In human liver microsomes, dasatinib was a weak time-dependent inhibitor of CYP3A4.
TIME-DEPENDENT INHIBITION
TYROSINE-PROTEIN KINASE FYN
TARGET -> INHIBITOR
IC50
Related Record Type Details
Structure of 2-(4-(6-((5-(8-CHLORO-4H-3,1-BENZOXAZIN-2-YL)THIAZOL-2-YL)AMINO)-2-METHYL-PYRIMIDIN-4-YL)PIPERAZIN-1-YL)ETHANOL
METABOLITE -> PARENT
Structure of N-DESHYDROXYETHYL DASATINIB
METABOLITE ACTIVE -> PARENT
Metabolite M4 was approximately equipotent to dasatinib
Structure of BMS-748730
METABOLITE ACTIVE -> PARENT
Structure of N-(2-CHLORO-6-METHYL-PHENYL)-2-((6-(4-(2-HYDROXYETHYL)-4-OXIDO-PIPERAZIN-4-IUM-1-YL)-2-METHYL-PYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
M5 and M6 were 10-fold less active than dasatinib
MAJOR
Structure of 2-(4-(6-((5-((2-CHLORO-6-METHYL-PHENYL)CARBAMOYL)THIAZOL-2-YL)AMINO)-2-METHYL-PYRIMIDIN-4-YL)PIPERAZIN-1-YL)ACETIC ACID
METABOLITE LESS ACTIVE -> PARENT
Structure of N-(2-CHLORO-6-(HYDROXYMETHYL)PHENYL)-2-((6-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)-2-METHYL-4-PYRIMIDINYL)AMINO)-5-THIAZOLECARBOXAMIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of DASATINIB ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966